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33.2 million people living with HIV-1 (see Global estimates of the num-
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and prevention, as well as the biomedical advances that have the 
potential to change the course of the pandemic.





























































































Global estimates of the number of individuals affected by the 
HIV/AIDS pandemic in 2007
	 Number	of	people	living	with	HIV	in	2007
Total 33.2 million (30.6–36.1 million)
Adults 30.8 million (28.2–33.6 million)
Women 15.4 million (13.9–16.6 million)
Children (<15 yr) 2.1 million (1.9–2.4 million)
	 People	newly	infected	with	HIV	in	2007
Total 2.5 million (1.8–4.1 million)
Adults 2.1 million (1.4–4.1 million)
Children (<15 yr) 420,000 (350,000–540,000)
	 Deaths	due	to	AIDS	in	2007
Total 2.1 million (1.9–2.4 million)
Adults 1.7 million (1.6–2.1 million)
Children (<15 yr) 290,000 (270,000–320,000)
Numbers in parentheses denote estimated ranges. Reproduced with 
permission from the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) (http://www.unaids.org; ref. 3).
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Source of infections with HIV-1 by region. An individual can become 
infected with HIV-1 from many sources, including contaminated blood 
and blood products (such as though medical injections, blood transfu-
sions, and injection drug usage [IDU]), an infected mother transmit-
ting the virus to her baby (before, during, or after birth and through 
breast milk), and through either vaginal or anal intercourse. The rela-
tive importance of a source of HIV-1 varies in different parts of the 
world. In some countries, infection with HIV-1 is mainly detected in 
specific groups at risk, including MSM, injecting drug users, sex work-
ers, and the regular partners of such persons. In most countries of 
sub-Saharan Africa, however, HIV-1 is self-sustaining in the general 
population through heterosexual intercourse in HIV-serodiscordant 
couples. MTCT, mother-to-child transmission. The data presented 
here were mostly generated for 2005, but some data are from earlier 
years. Reproduced with permission from the Global HIV Prevention 
Working Group (103).
Figure 2
HIV-1 viremia and HIV-1 shedding over time. The concentration of 
HIV-1 in blood and genital secretions varies dramatically depending 
on the stage of the disease. Shown here are data for HIV-1 viremia 
and HIV-1 shedding over time in men acutely or chronically infected 
with HIV-1. Measurements of HIV-1 RNA in blood plasma (gray) and 
seminal plasma (black) are displayed over 16 weeks. The data were 
generated from 16 acutely infected subjects, who contributed blood 
and semen at 60 and 34 time points, respectively, and from 25 chroni-
cally infected subjects, who contributed blood and semen at 123 and 
89 time points, respectively. The highest viral loads were detected at 
the first time point after infection and in people with advanced disease. 
Boxes and whiskers denote the 25th and 75th quartiles and total range 
of values. Internal circles and horizontal lines represent mean and 
median, respectively. Reproduced with permission from AIDS (15).
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Genomic maps of HIV-1 and HIV-2. Although HIV-1 and 2 have simi-
lar genetic structures, the DNA sequences differ by up to 40%. Both 
viruses have structural and accessory genes that influence replica-
tion and pathogenesis (Table 1). Many of these are shared between 
the two viruses, such as gag and pol; however, only HIV-1 has a 
gene that encodes Vpu, and Vpx is only encoded by HIV-2. Repro-
duced from ref. 146.
Table 1
HIV-encoded proteins and their functions
Protein	 Size	(kDa)	 Function	and	properties
Gag p24 Structural capsid protein
Gag p17 Myristoylated matrix protein
Gag p7 Nucleocapsid protein; helps in reverse transcription
Gag p6 Role in budding (L domain)
Polymerase (Pol) p66, p51 Reverse transcriptase; RNAse H; found inside the core
Protease (PR) p10 Posttranslation processing of viral proteins
Integrase (IN) p32 Viral cDNA integration
Envelope gp120 Envelope surface protein
Envelope gp41 Envelope transmembrane protein
TatA p14 Transactivation
RevA p19 Regulation of viral mRNA expression
Nef p27 Pleiotropic effects, can increase or decrease virus replication
Vif p23 Increases virus infectivity and cell-to-cell transmission; helps 
  in proviral DNA synthesis and/or in virion assembly
Vpr p15 Helps in virus replication; transactivation
VpuA,B p16 Helps in virus release; disrupts gp160-CD4 complexes
VpxC p15 Helps in viral entry and infectivity
TevA p26 Tat and Rev activities
ANot found associated within the virion. BOnly present with HIV-1. COnly encoded by HIV-2; may be a 
duplication of Vpr. Reproduced from ref. 146.
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the  epidemic  was  much  larger.  The  2000  International  AIDS 
Conference in Durban, South Africa, accelerated a breakthrough 
in worldwide access to HAART. Shortly before the Durban con-














































































































































Opportunities for preventing infection with HIV-1. Prevention efforts 
can be divided into four broad categories: those offered to HIV-1–neg-
ative subjects, especially those in high-risk groups (e.g., the offer of 
male circumcision, condoms); those offered to people with a strong 
likelihood of recent exposure to HIV-1 (e.g., topical microbicides, anti-
retroviral preexposure prophylaxis [PrEP]); those offered shortly after 
exposure (e.g., postexposure prophylaxis [PEP]), and those offered to 
people who are already infected (secondary prevention; e.g., the use 
of antiretroviral therapy to reduce viral load).
Table 2
Ongoing clinical trials to assess the effectiveness of orally administered antiretroviral drugs in preventing the acquisition of infection with HIV-1
Product	 Population	enrolled	in	trial	 Number	of	participants	 Site	of	trial	 Trial	sponsor	 Year	results		
	 	 	 	 	 expected
Tenofovir Male and female injecting drug users 2,000 Thailand CDC 2008
Tenofovir MSM 400 US CDC 2009
Truvada Heterosexual men and women 1,200 Botswana CDC 2010
Truvada MSM 3,000 South America, US,  NIH 2011
   South Africa, and Thailand
CDC, Centers for Disease Control and Prevention.
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viremia  in acute HIV-1  infection [abstract]. The 
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